Screening for Hereditary Transthyretin Amyloidosis in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (hATTR IN CIDP)
Summary
The purpose of this research study is to determine if some people diagnosed with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) may have another genetic disease that can cause nerve damage, called hereditary TTR amyloidosis (hATTR). hATTR is treated very differently than CIDP, so understanding if hATTR is sometimes incorrectly diagnosed as CIDP is important.
Eligibility
Eligible ages: 18 to 120
Inclusion criteria:
You are eligible for this study if you are:
1. Age 18-years or older.
2. Have a clinical diagnosis of CIDP by a neuromuscular specialist.
3. Are seeing for your disease in the University of Calgary Neuromuscular Clinic.
Exclusion criteria:
You are not eligible for this study if you are:
1. Unable to understand the informed consent process due to cognitive or language barriers.
Participate
Fill out the following form if you want to participate in this research
UCalgary Notice of Collection
The University of Calgary (UCalgary) respects your privacy and is
committed to ensuring the privacy of all students, staff, and community members. Your personal information is being
collected under the authority of section 4(c) of the Protection of Privacy Act (POPA). It will be collected, used
and disclosed for the purposes outlined in UCalgary’s
Notice of
Collection, Use and Disclosure of Personal Information and managed in accordance with UCalgary’s
Privacy
Management Program.
Your personal information may be input into automated systems to generate content or make decisions,
recommendations, or predictions. If you have questions regarding this notice or UCalgary’s collection,
use, or disclosure of your personal information, please contact
accessandprivacy@ucalgary.ca.
Additional information
Contact information
Dr. Gordon Jewett nmresearch@ucalgary.ca
Principal investigator:
Gordon Jewett
Clinical trial:
No
REB-ID:
REB23-0437